Herbst Kinsky advised Themis Bioscience GmbH on its EUR 40 mio Series D financing round with new investors Farallon Capital (USA), Adjuvant Capital (USA), Hadean Ventures (SWE/NOR) and Merck Sharp & Dohme (USA) as existing investors Global Health Investment Fund (USA), Omnes Capital (FRA), Ventech (FRA), Wellington Partners (DE) and aws Gründerfonds (AT).

The raised funds are intended to finance the market entry of the leading vaccine candidate against the Chikungunya virus and to develop a new vaccine for oncology and infectious diseases.

“We are delighted about the continuation of Themis success path. The high interest of such renowned investors in Themis is a confirmation of the attraction of the Austrian VC market. The magnitude of this financing round is – in the Austrian comparison – certainly extraordinary”, says Florian Steinhart, partner at Herbst Kinsky.

Herbst Kinsky´s team was led by Florian Steinhart (VC, Corporate) supported by Magdalena Wagner (VC, Corporate) and Alexander Höller (IP).